Generic placeholder image

Current Drug Therapy

Editor-in-Chief

ISSN (Print): 1574-8855
ISSN (Online): 2212-3903

Trends in the Treatment of Hepatocellular Carcinoma

Author(s): Janine M. Davies and Bert H. O'Neil

Volume 5, Issue 2, 2010

Page: [118 - 121] Pages: 4

DOI: 10.2174/157488510791065111

Price: $65

Abstract

HepatoCellular Carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer- related deaths. In unresectable disease, chemotherapy has modest response rates without a clear improvement in overall survival. Sorafenib is a multikinase inhibitor that recently demonstrated improved overall survival in two randomized clinical trials. This review paper outlines the basic treatment options for HCC by stage, followed by a discussion of key issues in the treatment and management of patients with HCC: the use of targeted therapies and/or chemotherapy in metastatic disease and in different ethnic groups; the potential use of combination therapies in earlier disease stages; and the role of imaging in the era of targeted therapy and the associated challenges.

Keywords: Hepatocellular carcinoma, sorafenib, multikinase inhibitor, treatment


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy